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Abstract
Background and Objectives—Over 12% of U.S. adults report past-year cannabis use, and
among those who use daily, 25% or more have a cannabis use disorder. Use is increasing as legal
access expands. Yet, cannabis use is not routinely assessed in primary care, and little is known
about use among primary care patients and relevant demographic and behavioral health subgroups.
This study describes the prevalence and frequency of past-year cannabis use among primary care
patients assessed for use during a primary care visit.
Methods—This observational cohort study included adults who made a visit to primary care
clinics with annual behavioral health screening, including a single-item question about frequency
past-year cannabis use (March 2015-February 2016; n=29,857). Depression, alcohol and other
drug use were also assessed by behavioral health screening. Screening results, tobacco use, and
diagnoses for past-year behavioral health conditions (e.g., mental health and substance use
disorders) were obtained from EHRs.
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Results—Among patients who completed the cannabis use question (n=22,095; 74% of eligible
patients), 15.3% (14.8–15.8%) reported any past-year use: 12.2% (11.8%–12.6%) less than daily
and 3.1% (2.9%–3.3%) daily. Among 2,228 patients 18–29 years, 36.0% (34.0%–38.0%) reported
any cannabis use and 8.1% (7.0%–9.3%) daily use. Daily cannabis use was common among men
18–29 who used tobacco or screened positive for depression: 25.5% (18.8%–32.1%) and 31.7%
(23.3%–40.0%), respectively.
Conclusions—Cannabis use was common in adult primary care patients, especially among
younger patients and those with behavioral health conditions. Results highlight the need for
primary care approaches to address cannabis use.
Keywords
Primary health care; screening; Cannabis

INTRODUCTION
Cannabis is the most commonly used drug in the United States, after alcohol and tobacco.1
As of 2013, 13% of U.S. adults – nearly 20 million people - used cannabis in the past year,
and over 8 million used daily.1 Nearly 3 in 10 adults who use cannabis have a cannabis use
disorder, defined as meeting 2 or more of 11 substance use disorder criteria (Table 1).2,3 The
prevalence of a cannabis use disorder increases with increasing frequency of use 1,3,4
With expanding legalization of cannabis use, the number of cannabis users—and daily
cannabis users at greatest risk for a cannabis use disorder4—is projected to grow over the
next 5–10 years.5 Medical cannabis use is now legal in 29 states and nonmedical use in 8,
including California, and the District of Columbia, with more states considering
legalization.6,7 Sale of cannabis for nonmedical use, including dried plant materials and
increasingly, a wide variety of highly-potent cannabinoid products, began in 2014 in
Colorado and Washington State, with restricted start-up sales beginning in 2015 for Oregon
and in 2016 for Alaska.8,9 Yet, to our knowledge, cannabis use is not routinely assessed in
U.S. primary care settings. As cannabis use increases, primary care providers may want to
know when patients use cannabis regularly.10
No U.S. study has evaluated the population-based prevalence of patient-reported cannabis
use among primary care patients, particularly in a state where nonmedical use is legal.
Kaiser Permanente Washington (formerly Group Health), an integrated health system in
Washington State, is currently implementing routine behavioral health screening as part of
behavioral health integration in primary care clinics. At the request of providers, in the
context of state legalization, a question about cannabis use was added to the behavioral
health screen before a question about illicit drug use.11 The purpose of this study was to
assess the prevalence and frequency of self-reported past-year cannabis use among primary
care patients. Specifically, the prevalence and frequency of cannabis use is described in the
total primary care sample, as well as within demographic and behavioral health subgroups.
The study also addresses implications for primary care for patients who use cannabis.
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METHODS
Setting
Kaiser Permanente Washington, a nonprofit health care system with 25 primary care sites
throughout Washington State, implemented annual behavioral health screening, including a
question about cannabis use, for adults in 3 primary care sites starting in March 2015.
Implementation of behavioral health screening was staggered across the three sites, which
were chosen for their receptivity to implementation and community representativeness. The
sites, spread across 90 miles in Western Washington, enrolled about 80,000 patients (17,000
– 37,000 per clinic). Site A initiated behavioral health screening in March 2015 (2 of 3
primary care clinics within the site); Site B initiated in early October (2 of 4 clinics); and
Site C initiated in late October in (1 of 2 clinics). Staff at each site assisted with work flow
development for behavioral health screening and met regularly to review and improve
screening prevalence (target 80%). Electronic health record (EHR) prompts alerted staff
when patients were due for screening. After check-in, patients completed a 7-item
behavioral health screen (described below) on paper. Medical assistants typically entered
results into the EHR and shared the results with the provider prior to the patient-provider
visit.
Data Source and Study Population
This observational cohort study obtained study data, including behavioral health screen
results and patient demographic and clinical characteristics, from Kaiser Permanente
Washington’s EHR. Patients 18 years and older were included if they attended an in-person
visit with a primary care provider in one of the 3 participating primary care sites from study
start (i.e., after initiation of screening at each site) through mid-February 2016. Patients with
EHR documentation of a response to the cannabis question during the study period,
indicating question completion, comprised the study sample. This study received approval
and waivers of consent and HIPAA authorization from the Kaiser Permanente Washington
Health Research Institute Institutional Review Board.
Measures
The 7-item Behavioral Health Screen
Past-Year Cannabis Use: The single-item cannabis use question, modeled after the third
question of the World Health Organization’s (WHO) 10-item AUDIT,12 asked about the
frequency of past-year cannabis use (i.e., “How often in the past year did you use
marijuana?” - “never”, “less than monthly”, “monthly”, “weekly”, and “daily or almost
daily”). The response options are identical to the second question of the WHO ASSIST
questionnaire.13 A categorical variable for the frequency of past-year cannabis use was
defined as none (“never”), less than daily (“less than monthly”, “monthly” and “weekly”)
and daily (“daily or almost daily”). Any response other than ‘never’ was considered positive
for any past-year cannabis use. The term ‘marijuana’ was used in the question as it is the
most commonly used U.S. cannabis term.14 Marijuana use was not defined and could
include nonmedical and medical use.
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Additional Behavioral Health Screen items: The 7-item screen also included the 2-item
Patient Health Questionnaire (PHQ-2) to assess possible depression in the past two weeks
(item scores 0–3; scores of 2 or 3 were positive for depression)15 and the 3-item Alcohol
Use Disorders Identification Test–Consumption (AUDIT-C) questionnaire to assess
unhealthy alcohol use in the past year (total scores of ≥3 for women and ≥4 for men were
positive for unhealthy alcohol use).16 A single-item screen for frequency of past-year illicit
drug use or nonmedical use of prescription medication, which followed the cannabis screen,
was adapted from a validated screen11 and had response options identical to the cannabis
screen, with any response other than ‘never’ positive for past-year illicit drug use/medication
misuse. In the uncommon case that a patient completed the 7-item screen more than once
during the study period (2.4% of patients), the highest score for each condition-specific
screen, if different, was used.
Demographic and Other Behavioral Health Conditions—Gender (women/men),
age (18–29, 30–49, 50–64, ≥65), race/ethnicity (black, Hispanic, other, white, unknown)17
were extracted from the EHR at the time of each patient’s initial in-person visit to the sites
during the study period. Behavioral health characteristics were selected based on their
association with cannabis use. Current tobacco use was based on any EHR documentation in
the year prior to initial visit that the patient reported currently using tobacco. Diagnostic
codes based on ICD-9-CM (prior to October 1, 2015) and ICD-10-CM (as of October 1,
2015) documentation in the EHR by providers for conditions addressed or considered during
an encounter were used to classify mental health and substance use disorders recognized in
the year prior to the cannabis screen. Mental health disorders in the past year were
categorized into major depressive disorders, anxiety disorders, including generalized
anxiety, panic, phobias and PTSD, and serious mental illness, including schizophrenia,
bipolar disorder and psychosis. Substance use disorders in the past year were categorized
into alcohol use disorders, cannabis use disorders and other drug use disorders (i.e., does not
include nicotine, alcohol or cannabis). Consistent with the use of the cannabis use question
as routine clinical assessment of the frequency of use (i.e., not as a diagnostic tool for a
disorder), patients with a cannabis use disorder were included in the study. Composite
indicators for any mental health disorder (e.g., depression, anxiety, serious mental illness)
and any non-cannabis substance use disorder (e.g., alcohol and other drug use disorders)
were also evaluated.
Analyses
Analyses described sample characteristics, including the prevalence and frequency of pastyear cannabis use. The prevalence and frequency of past-year cannabis use, along with 95%
confidence intervals, were also calculated among patient subgroups based on demographic
(e.g., patients within each category of gender, age, and race/ethnicity) and behavioral health
(e.g., patients who screened positive on a behavioral health screen or had documentation of a
behavioral health condition/diagnosis) characteristics.1 All analyses were conducted in Stata
Version 13.1 MP edition.
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RESULTS
A total of 29,857 patients visited the 3 primary care sites during the study period, and of
those, 22,095 (74.0%) patients had EHR documentation of the question about past-year
cannabis use and were included in the study sample. Among patients who made a visit, those
who completed the cannabis use question were similar to those who did not (data available
upon request).
Most patients in the study sample were female, white and older; 9.7% reported current
tobacco use and 15.0% had a major depression diagnosis in the past year [Table 2]. Among
patients in the sample, 15.3% (95% CI 14.8%–15.8%) reported any cannabis use in the past
year: 7.7% (7.3%–8.0%) less than monthly; 2.2% (2.0%-2.4%) monthly; 2.3% (2.1%–2.5%)
weekly; and 3.1% (2.9%–3.3%) daily. Among those who reported any cannabis use, 50.1%
(48.4%–51.8%) reported infrequent use (<monthly), 14.6% (13.5%–15.9%) and 15.0%
(13.8%–16.2%) reported monthly and weekly use, respectively, and 20.3% (19.0%–21.7%)
reported daily use.
The prevalence and frequency of past-year cannabis use was high among men and patients
18–29 years old [Figure 1 Panel A]. In particular, 32.1% (29.7%–34.5%) of women 18–29
years reported any cannabis use and 6.1% (4.9%–7.4%) reported daily use, while 43.6%
(40.1%–47.2%) of men 18–29 years reported any cannabis use and 12.1% (9.7%–14.4%)
daily use.
Compared to the prevalence among all primary care patients, any and daily past-year
cannabis use was higher among patients in each behavioral health subgroup [Figure 1 Panel
B]. Among 5,340 patients with a mental health disorder, 18.9% (17.9%–20.0%) and 4.5%
(3.9%-5.0%) reported any and daily past-year cannabis use, respectively, while among 558
patients with a non-cannabis substance use disorder, 31.0% (27.3%–35.0%) and 8.4%
(6.4%–11.0%) reported any and daily past-year cannabis use, respectively. Among 109
patients with a cannabis use disorder documented in the past year, 84.4% (76.3%–90.1%)
and 49.5% (40.2%–58.9%) reported any and daily past-year use, respectively.
When patient characteristics were combined, the prevalence of cannabis use was higher in
some groups [Table 3; Appendix A]. For example, among men 18–29 years who screened
positive for depression or reported tobacco use, 63.0% (55.6%–70.4%) and 65.8% (57.3%–
74.4%), respectively, reported any cannabis use, with 25.5% (18.8%–32.1%) and 31.7%
(23.3%–40.0%), respectively, reporting daily use.
To identify patient characteristics independently associated with increased odds of past-year
cannabis use, two post-hoc logistic regressions, with binary outcomes for any use and daily
use, were performed and adjusted for all measured patient demographic and clinical
characteristics.18 The adjusted odds of any use were higher among patients who were male,
younger, current tobacco users, or had depression, anxiety, unhealthy alcohol use, or illicit
drug use/prescription medication misuse, with similar results for daily use (Table 4). Patients
18–29 years had the highest adjusted odds of any use and daily use, 7.34 (6.42–8.40) and
4.82 (3.67–6.31), respectively, when compared to patients 65 years and older.
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DISCUSSION
More than 1 in 6 primary care patients in a state where cannabis use is legal reported using
cannabis when screened for depression, unhealthy alcohol use, cannabis and illicit drug use
as part of routine behavioral health screening. Cannabis use was particularly common
among young adults—nearly 4 in 10 reported past-year use—and among those with tobacco
use, unhealthy alcohol use, illicit drug use, or mental health or substance use disorders.
Daily cannabis use was reported by 1 in 12 young adults and nearly 1 in 20 patients with a
mental health disorder. However, when multiple characteristics associated with use were
combined (e.g. young men who used tobacco or screened positive for depression), the
prevalence of daily use exceeded 25%. These relationships persisted after adjustment, with
younger patients and those with other substance use and behavioral health concerns having
higher adjusted odds of any and daily cannabis use.
As states legalize use of cannabis, the perception that cannabis use is safe has increased.19,20
However, frequent and/or high-potency cannabis use—irrespective of the purpose—
increases the risk of cannabis use disorder. Moreover, the concentration of
tetrahydrocannabinol (THC), the main psychoactive and addictive component in cannabis,
has increased in cannabis plants from an average of 3% to 12% in recent years, with some in
excess of 20%, contributing to a higher prevalence of cannabis use disorders.21 New
methods of administration and new products, including concentrated hash oil, synthetic
cannabinoids and edibles, have further increased the per-use potency of cannabis and the risk
of addiction.22,23 More than 9% of lifetime cannabis users will develop and 25%–50%
patients who use daily are at risk for a cannabis use disorder.3,24,25 Young adults have the
greatest risk, with 35% of current users meeting criteria for a cannabis use disorder.26 Young
adults may also be most adversely impacted, as frequent use diminishes educational,
occupational, cognitive and social development.27,28 Patients who use cannabis for medical
purposes, the majority of whom also use recreationally, are more likely to use multiples
times per day and to use highly potent forms of cannabis to manage symptoms.8 All of these
factors increase the risk that patients who use cannabis will develop a cannabis use disorder.
Cannabis use poses other significant health risks, which increase with the frequency and
intensity of use: 1) central nervous system impairment, acute (e.g., judgment, coordination)
and chronic (e.g., memory, cognition),29 2) exacerbation and persistence of psychiatric
symptoms (e.g., depression, psychosis),30 3) development of other drug use disorders,
including nicotine and alcohol31 4) prescription medication interactions (e.g.,
antidepressants, opioids),32 5) prenatal exposure during pregnancy,33 6) pulmonary
symptoms29 and 7) accidents, particularly motor vehicle accidents.34 Finally, frequent use of
cannabis can cause significant withdrawal, which appears clinically similar to tobacco and
opioid withdrawal, with symptoms of anxiety, irritability, depressed mood, disturbed sleep,
decreased appetite and restlessness.35
Although cannabis use has established health risks, the U.S. Preventive Services Task Force
does not currently recommend routine preventive screening for cannabis or other illicit drug
use in primary care due to the lack of known effective brief primary care interventions to
decrease drug use.36 However, the value of asking about cannabis use, separate from brief
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interventions, has not been investigated. Results of this study suggest primary care patients
are willing to report cannabis use, including daily use, as part of behavioral health screening
documented in their EHRs.
Knowledge of patients’ cannabis use could help providers initiate conversations with
patients, allowing for assessment of the reasons, perceived risks/benefits, and intensity of
cannabis use. While cannabis may have therapeutic value for promoting appetite and treating
nausea, spasticity, chronic pain, and neuropathic pain, providers may want to advise patients
about more effective and/or safer treatment alternatives available for most conditions.27,37
Additionally, there is inadequate evidence for the efficacy of cannabis use for some
conditions/symptoms, like depression and anxiety, which can be worsened by cannabis
use.38 Because of the potential for harm, women should be advised against cannabis use
during pregnancy.39
For patients who use cannabis regularly, assessment of the intensity (e.g., frequency per-day,
method of administration) and potency of use, as well as symptoms of a cannabis use
disorder using questionnaires like the Cannabis Use Disorders Identification Test40 or
DSM-5 substance use disorder criteria,41 can provide additional information about a
patient’s risk for cannabis-related consequences, including addiction. For patients who have
a cannabis use disorder, cognitive behavioral and motivational enhancement therapies are
effective, separately and in combination, in reducing cannabis use and the severity of
disorder symptoms.42,43 Contingency management can augment treatment outcomes when
paired with these therapies.42,43 No medication has proven broadly effective nor been
approved for treatment of cannabis use disorders.42 Most pharmacotherapies evaluated,
including antidepressants, bupropion, buspirone, and atomoxetine, have shown little value in
treating cannabis use disorders.44 Although gabapentin, N-acetylcysteine (NAC), especially
NAC for 18–21 year olds,45 and medications containing THC have shown promise, further
investigation is needed. As most patients with a cannabis use disorder will not seek care in
formal treatment settings,1,46 behavioral and other effective treatments for cannabis use
disorders in primary care are needed.
There are several limitations to this study. Although the question about cannabis use was
adapted from well-validated alcohol and substance use measures, it has not been validated
against a gold-standard interview for cannabis use. However, the question has high face
validity, and underreporting is expected,47 making estimates of the prevalence of any
cannabis use in this study (15%) conservative. The prevalence of cannabis use in this study
is higher than the national prevalence (12.5%),1 consistent with findings that the prevalence
of use is higher in states with legalized use.48 Furthermore, the frequency of cannabis use
among young adults in this sample of Washington State primary care patients is comparable
to that reported by young adults in the same state on a 2014 confidential internet-based
survey.19 Although there was no evidence of selective non-response, a quarter of eligible
patients did not complete behavioral health screening. Reasons included that medical
assistants did not offer the screen (e.g., were busy or staffing was low), patients did not
speak/read English, or the primary care provider was behind schedule. The prevalence of
cannabis and other substance use disorders in this study, based on documentation by
clinicians in the EHR in the previous year, was low compared to US population
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estimates,26,49 in contrast to rates for mental health diagnoses,50 suggesting underrecognition of substance use disorders. Research is needed to determine whether routine
assessment of cannabis and other drug use as part of behavioral health screening increases
the prevalence of recognized substance use disorders. Although a question about frequency
of past-year cannabis use was practical for routine screening, the question omitted relevant
dimensions of use (e.g., potency, frequency per-day, medical vs. nonmedical use). Future
studies of cannabis use among primary care patients need to assess differences in medical
and nonmedical use and the intensity, potency and methods of cannabis used. Finally, this
study was restricted to adults and similar research is needed on younger patients.
In summary, this study of the prevalence and frequency of cannabis use among primary care
patients, in a state with legalized use, found that most primary care patients who completed
recommended routine behavioral health screening (e.g., depression and alcohol),51,52 also
completed a question about past-year cannabis use. Additionally, while 15% of all primary
care patients reported any past-year cannabis use, the prevalence was much higher in
important patient subgroups. Most notably, more than 1 in 4 younger men who used tobacco
or screened positive for depression reported high-risk daily cannabis use. Routinely asking
about cannabis use could promote recognition of patients who may benefit from primary
care discussions about their cannabis use.
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Appendix A. The prevalence and frequency of past-year cannabis use
among patient demographic and behavioral health subgroups
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Appendix B. Among young patients 18–29 years old with a documented
condition, diagnosis or behavioral health screen, the prevalence of pastyear cannabis use
Note. Any use is the summed total of <monthly/monthly/weekly use and daily use.
Documented conditions and diagnoses were in the year prior to the clinic visit
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Figure 1.

The prevalence of past-year cannabis use among patients in age and gender subgroups (panel
A) and among those with a documented condition, diagnosis or behavioral health screen
(panel B)
Note. Any use is the summed total of <monthly/monthly/weekly use and daily use.
Documented conditions and diagnoses were in the year prior to the clinic visit
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Continued cannabis use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of cannabis

Important social, occupational, or recreational activities are given up or reduced because of cannabis use

Recurrent cannabis use in situations in which it is physically hazardous

Cannabis use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by cannabis

Tolerance, as defined by either a (1) need for markedly increased cannabis to achieve intoxication or desired effect or (2) markedly diminished effect with continued use of the same
amount of cannabis

Withdrawal, as manifested by either (1) the characteristic withdrawal syndrome for cannabis or (2) cannabis is taken to relieve or avoid withdrawal symptoms

6

7

8

9

10

11

Note: The severity of a cannabis use disorder is defined as: mild (2 or 3 symptoms); moderate (4 or 5); and severe (6 or more); Reprinted with permission from the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition, (Copyright 2013). American Psychiatric Association. All Rights Reserved.

Recurrent cannabis use resulting in a failure to fulfill major role obligations at work, school, or home

5

A great deal of time is spent in activities necessary to obtain cannabis, use cannabis, or recover from its effects

3

Craving, or a strong desire or urge to use cannabis

There is a persistent desire or unsuccessful efforts to cut down or control cannabis use

2

4

Cannabis is often taken in larger amounts or over a longer period than was intended.

1

A problematic pattern of cannabis use leading to clinically significant impairment or distress, as manifested by at least 2 of the following, occurring within a 12-month period:

Diagnostic and Statistical Manual of Mental Disorders-5th edition (DSM-5) criteria for a cannabis use disorder

Table 1
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Table 2

Primary care adult patients who attended pilot sites and were screened for past-year cannabis use (n 22,095)
N

%

Gender
Women
Men

13,182

(59.7)

8,913

(40.3)

Age categories
18–29

2,228

(10.1)

30–49

5,194

(23.5)

50–64

6,774

(30.7)

≥65

7,899

(35.8)

490

(2.2)

Race/ethnicity
Black
Hispanic

997

(4.5)

Other

1,972

(8.9)

White

17,993

(81.4)

643

(2.9)

2,133

(9.7)

Major depression

3,323

(15.0)

Anxiety disorder

Unknown
Tobacco use*
Diagnoses in prior year*

2,994

(13.6)

Serious mental illness‡

704

(3.2)

Alcohol use disorder

396

(1.8)

Cannabis use disorder

109

(0.5)

Other drug use disorder

200

(0.9)

Depression (PHQ-2) ‡

3,582

(16.3)

Unhealthy alcohol use‡

5,863

(26.6)

363

(1.7)

Behavioral health screens

Any illicit drug use/Rx drug misuse‡

*

Assessed in the year prior to clinic visit

†

Includes diagnoses for bipolar disorder, psychosis and schizophrenia

‡

Total N varies due to some patients not completing items of Behavioral Health screen: PHQ-2 (n 22,081); AUDIT-C (n 22,034); drug screen (n
21,945)
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40.3

(34.1–46.5)

53.6

(46.3–61.0)

(n 243)

(n 179)

52.6

(41.4–63.7)

(n 78)

(n 120)

65.8

(7.2–15.1)

(12.7–24.1)

(57.3–74.4)

11.1

(23.5–35.0)

(28.2–42.2)

18.4

29.2

(53.5–65.9)

(39.0–53.7)

35.2

59.7

46.4
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Daily

> Daily

None

14.1

(6.3–21.9)

(23.3–40.0)

(27.6–49.4)

(25.6–42.7)

31.7

38.5

(36.3–58.6)

(25.6–42.7)

34.2

47.4

34.2

Frequency of use

Any use

Daily

> Daily

None

Frequency of use

Any use

%
(95% CI)

%

(95% CI)

Major Dep

Tobacco use

(7.4–22.5)

14.9

(27.7–48.2)

37.9

(36.6–57.7)

47.1

(42.3–63.4)

52.9

(n 87)

(4.7–11.2)

8.0

(23.7–34.7)

29.2

(57.0–68.7)

62.9

(31.3–43.0)

37.1

(n 264)

(95% CI)

%

Anxiety

(−2.8–18.2)

7.7

(19.4–57.6)

38.5

(34.3–73.4)

53.9

(26.6–65.7)

46.2

(n 26)

(0.3–13.5)

6.9

(20.6–45.0)

32.8

(47.6–73.1)

60.3

(27.0–52.4)

39.7

(n 58)

(95% CI)

%

Serious Mental Illness

(8.6–58.1)

33.3

(3.5–49.9)

26.7

(14.3–65.7)

40.0

(34.3––85.7)

60.0

(n 15)

57.1

(7.8–54.7)

31.3

(24.7–75.3)

50.0

(−1.0–38.5)

18.8

(61.5–101.0)

81.3

(n 16)

(3.4–32.3)

17.9

(20.9–57.7)

39.3

(24.2–61.5)

42.9

(38.5–75.8)

MEN 18–29 years

(4.2–37.4)

20.8

(17.7–57.3)

37.5

(21.5–61.8)

41.7

(38.2–78.5)

58.3

(n 24)

(n 28)

(95% CI)

%

Other Drug Use
Disorder

WOMEN 18–29 years

(95% CI)

%

Alcohol Use disorder

------------------- Conditions/Diagnoses in prior year -------------------

(18.8–32.1)

25.5

(30.2–45.0)

37.6

(29.6–44.4)

37.0

(55.6–70.4)

63.0

(n 165)

(11.3–19.1)

15.2

(27.5–37.6)

32.5

(46.9–57.7)

52.3

(42.3–53.1)

47.7

(n 329)

(95% CI)

%

Dep (PHQ-2)

(11.6–20.9)

16.3

(42.4–55.1)

48.8

(28.9–41.1)

35.0

(58.9–71.1)

65.0

(n 240)

(6.7–11.6)

9.2

(36.4–44.9)

40.7

(45.9–54.5)

50.2

(45.5–54.1)

49.8

(n 524)

(95% CI)

%

Unhealthy alcohol use

(17.8–9.8)

28.8

(51.9–75.4)

63.6

(1.1–14.0)

7.6

(86.0–98.9)

92.4

(n 66)

(11.3–29.2)

20.3

(40.8–63.0)

51.9

(17.9–37.8)

27.9

(62.2–82.1)

72.2

(n 79)

(95% CI)

%

Illicit drug use/Rx
drug misuse

-------- Behavioral Health Screens --------

Among young patients 18–29 years old with a documented condition, diagnosis or positive Behavioral Health screen, the prevalence and frequency of
past-year cannabis use

Table 3
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3.26
2.61
--

30–49

50–64

≥65†

-1.00

White†

Unknown
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(0.69

0.89
1.41

Alcohol use disorder

Other drug use disorder

1.77
2.76
5.19

Depression (PHQ-2)*

Unhealthy alcohol use

Any illicit drug use/Rx drug misuse

Behavioral health screens

(1.09
(1.18

1.23
1.45

Anxiety disorder

Serious mental illness

(4.05

(2.54

(1.61

(0.98

(1.20

(1.79

(0.80

--

(0.61

(0.76

(0.51

--

(2.33

(2.90

(6.42

(1.55

--

1.92

2.93) §

3.89
1.47
2.86

3.00) §
6.66) §

0.94

1.96) §

2.04)

0.94

1.51

1.16)

1.23

1.79) §

1.20

2.92

1.34

--

1.38)

1.52) §

2.23) §

1.25)

--

0.70

0.83) §

0.75
1.09

1.11)

0.91)

--

2.75

3.68) §

--

4.82

1.87

--

(2.08

(1.24

(3.28

(0.54

(0.61

(1.05

(0.98

(0.96

(2.43

(0.91

--

(0.52

(0.76

(0.43

--

(1.49

(2.13

(3.67

(1.59

--

Daily use
Adjusted OR

8.40) §

1.83)§

--

95% CI

1.35

Major depression

Diagnoses in prior year‡

2.00

0.71

Other

Current tobacco use‡

0.68
0.92

Black

Hispanic

Race

7.34

1.68

--

18–29

Age categories

Men

Women†

Gender

Adjusted OR

Any use

Adjusted* odds of any and daily past-year cannabis use by patient characteristic

Table 4

3.95) §

1.74) §

4.60) §

1.62)

1.46)

2.17)

1.55)

1.49)

3.52) §

1.97)

--

0.96)

1.57)

1.32)

--

2.48) §

3.53) §

6.31) §

2.21) §

--

95% CI
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§

‡

†

*

0.03

Adjusted OR
0.03) §

95% CI
(0.03
0.00

Adjusted OR
(0.00

Daily use

0.01) §

95% CI

p-value <0.001; p-value <0.05

Assessed in the year prior to clinic visit;

Referent group;

Adjusted for all patient characteristics: gender, age, race, ethnicity, current tobacco use, diagnoses and behavioral health screens;

constant

Any use
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